Note: This is an archived page that is not updated.
Glue grants were large-scale collaborative project awards (U54s)
whose purpose was to enable the self-assembly of multidisciplinary
teams of investigators to solve major biomedical problems of their
own selection within the NIGMS mission. The problems identified had
to require a large-scale approach and have reached a stage to be
feasibly solved within a 10-year period. The self-assembled teams
were expected to involve a number of independently funded
investigators, selected for expertise and eminence and not
location, who were already working on aspects of the selected
biomedical problem. A strong leader and centralized project
leadership were required.
Glue grants provided a substantial level of resources to
participants to coordinate and integrate their research toward
collective goals, expressed as milestones and updated annually. The
funding provided was not meant to supplement ongoing or engender
new hypothesis-driven projects, but to bridge and synergize already
funded individual efforts toward the solution of the overarching
problem selected. For this large-scale effort, teams were expected
to develop state-of-the-art, large-scale technologies and to create
the infrastructure for high-volume data collection, coordination,
management and analysis.
It was expected that glue grants would result in important,
qualitative research advances that could not be achieved by
investigators working independently or by using other funding
mechanisms. It was also expected that research resources, including
data, software, cell lines, animal models and other unique reagents
generated by a glue grant, would be shared with the larger
scientific community.The paramount considerations for large-scale
collaborative project awards were the potential impact on
biomedical science, the value added over individual grant
approaches and the likelihood of success in a 10-year time
Responses to these announcements resulted in 15 Phase I awards
and seven Phase II awards. Five of those Phase II awards resulted
in a second Phase II award. Two Phase II awards were more
recently made for an initial 5-year period and were not included in
this outcomes assessment. The average Phase II award was $4.9
million per year (direct costs) and $7.4 million per year (total
costs). The cost of the entire glue grant program over 10
years was 1.8 percent of the total NIGMS budget.
The names of the NIGMS staff members who served as program
officials and as scientific liaisons for these cooperative
agreement awards are included in the
complete list of participants.
Additional reference on the origins of the glue grant
Rogers ME, Onken J. The National Institute of General Medical
Sciences Glue Grant Program.
Olson GM, Zimmerman A, Bos N, editors. Scientific collaboration on
the internet. Cambridge: The MIT Press, 2008.
In addition to the glue grant projects mentioned above, one
further project that was submitted in response to the initial
request for applications was funded by the National Institute of
Allergy and Infectious Diseases (NIAID): Systems Approach to Innate
Immunity-Inflammation-Sepsis (principal investigator, Richard J.
Ulevitch, Scripps Research Institute). This project was funded as a
cooperative agreement for 5 years. It was continued under a
contract. NIAID issued a request for applications to continue its
support of collaborative research in this area. See: Systems Approach to Immunity and Inflammation
(U19). Outcomes of this project were not considered in this
assessment, but would be useful to review and compare with the
outcomes of the NIGMS-managed glue grants.
($ in millions)
This page last reviewed on
4/13/2015 3:16 PM
Connect With Us: